Literature DB >> 3985602

Once-daily ceftriaxone therapy for serious bacterial infections in children.

B L Congeni, T Chonmaitree, T A Rakusan, Q T Box.   

Abstract

Ceftriaxone administered as a single daily dose of 50 mg/kg was evaluated in the treatment of 35 children with a variety of nonmeningitic bacterial infections. In two of the patients, the drug was discontinued before the response to the drug could be evaluated. All of the remaining patients had a satisfactory response. In 22 of the patients, plasma was available for the determination of ceftriaxone levels 1 h after a dose and immediately before the next dose. All but one of these patients had trough ceftriaxone levels which exceeded the MIC of the infecting organism, although marginally so for Staphylococcus aureus. Ceftriaxone appears to be safe and effective in the treatment of a variety of bacterial pathogens in children when administered at a single daily dose of 50 mg/kg. This drug may be especially useful in those patients in whom outpatient antibiotic therapy is contemplated or in whom maintenance of intravenous access is difficult.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3985602      PMCID: PMC176234          DOI: 10.1128/AAC.27.2.181

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

2.  Efficacy of ceftriaxone in treatment of serious childhood infections.

Authors:  E G Chadwick; E M Connor; S T Shulman; R Yogev
Journal:  J Pediatr       Date:  1983-07       Impact factor: 4.406

3.  Comparison of ceftriaxone with standard therapy for bacterial meningitis.

Authors:  R W Steele; R W Bradsher
Journal:  J Pediatr       Date:  1983-07       Impact factor: 4.406

4.  Single-dose ceftriaxone pharmacokinetics in pediatric patients with central nervous system infections.

Authors:  E G Chadwick; R Yogev; S T Shulman; R E Weinfeld; I H Patel
Journal:  J Pediatr       Date:  1983-01       Impact factor: 4.406

5.  Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin.

Authors:  H C Neu; N J Meropol; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

6.  Single-dose pharmacokinetics of ceftriaxone in infants and young children.

Authors:  U B Schaad; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

7.  Ceftriaxone versus ampicillin and chloramphenicol for treatment of bacterial meningitis in children.

Authors:  M A del Rio; D Chrane; S Shelton; G H McCracken; J D Nelson
Journal:  Lancet       Date:  1983-06-04       Impact factor: 79.321

8.  Twice daily ceftriaxone therapy for serious bacterial infections in children.

Authors:  T Chonmaitree; B L Congeni; J Munoz; T A Rakusan; K R Powell; Q T Box
Journal:  J Antimicrob Chemother       Date:  1984-05       Impact factor: 5.790

9.  Ceftriaxone for the treatment of serious infections.

Authors:  R W Steele; R W Bradsher
Journal:  Am J Dis Child       Date:  1983-11

10.  Single daily dose treatment of severe refractory infections with ceftriaxone. Cost savings and possible parenteral outpatient treatment.

Authors:  J D Baumgartner; M P Glauser
Journal:  Arch Intern Med       Date:  1983-10
View more
  1 in total

1.  Aztreonam in the treatment of severe urinary tract infections in pediatric patients.

Authors:  F Rusconi; B M Assael; A Boccazzi; R Colombo; R M Crossignani; L Garlaschi; L Rancilio
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.